Idogen AB (OSTO:IDOGEN) Research & Development: kr0.00 Mil (TTM As of Mar. 2023)


OSTO:IDOGEN Idogen AB OSTO:IDOGEN
21 GF Score
Price kr0.12
View Full Analysis

What is Idogen AB Research & Development?

Idogen AB OSTO:IDOGEN 21 Research & Development is kr0.00 Mil as of Mar. 2023. GuruFocus rates OSTO:IDOGEN with a GF Score™ of 21/100.

Research & Development is the aggregate amount of research and development expenses during the year. Idogen AB's Research & Development for the three months ended in Mar. 2023 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2023 was kr0.00 Mil.

Idogen AB  (OSTO:IDOGEN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Idogen AB Research & Development Related Terms

Idogen AB Research & Development Historical Data

* Premium members only.

The historical data trend for Idogen AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idogen AB Research & Development Chart

Idogen AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Idogen AB Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:IDOGEN
21GF Score
Idogen AB OSTO:IDOGEN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idogen AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Idogen AB (OSTO:IDOGEN) has a Research & Development of kr0.00 Mil as of Mar. 2023. Research and development expense is the total cost for research and development activities. View historical data on Idogen AB and its competitors.
Is Idogen AB's Research & Development too high?
Idogen AB's current Research & Development is kr0.00 Mil. Overall, Idogen AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Idogen AB's Research & Development compare to REGN and VRTX?
Idogen AB's Research & Development of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Idogen AB and its competitors. Idogen AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idogen AB stock overvalued right now?
Idogen AB (OSTO:IDOGEN) has a current Research & Development of kr0.00 Mil. The current Research & Development is kr0.00 Mil. Idogen AB's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Idogen AB (OSTO:IDOGEN), the current Research & Development is kr0.00 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Idogen AB Business Description

Address Medicon Village, Scheelevagen 2, Lund, SWE, 223 81
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
21GF Score

Get the complete analysis for OSTO:IDOGEN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price